Veracyte Inc Earnings Call Signals Profitable Growth

Veracyte Inc ((VCYT)) has held its Q1 earnings call. Read on for the main highlights of the call.

Veracyte Inc’s latest earnings call struck an upbeat tone, with management highlighting strong double‑digit growth, expanding margins, and powerful cash generation. Executives balanced this optimism with a clear-eyed view of clinical, reimbursement, and seasonal risks, but insisted these do not overshadow the company’s accelerating commercial and operational momentum.

Broad-Based Revenue Strength

Veracyte reported total revenue of $139.1 million, up 21% year over year, underscoring robust demand across its portfolio. Testing revenue did most of the heavy lifting at $135.1 million, climbing 26% and reinforcing the company’s position in precision oncology diagnostics.

Testing Volumes Continue to Climb

Total testing volume reached about 45,200 tests, up 19% year on year, within an overall volume base of roughly 47,600. Decipher volumes surged to about 28,000 tests, gaining 24%, while Afirma added about 17,200 tests, a solid 12% increase despite a more mature franchise.

Pricing Power and ASP Tailwinds

The company’s blended testing average selling price reached $2,980, rising 6% year over year, with normalized ASP at $2,900 for 3% growth excluding prior‑period collections. Decipher showed the strongest pricing momentum, outpacing Afirma and helping lift overall revenue quality.

Margin Expansion and Profitability Upside

Non‑GAAP gross margin improved to 75.7%, expanding 350 basis points from a year ago, while testing gross margin rose to 70.4%, up 230 basis points. Profitability followed suit, with GAAP net income of $28.7 million and adjusted EBITDA of $42.8 million, or 30.8% of revenue, well above the firm’s long‑term 25% target.

Cash Generation and Balance Sheet Firepower

Veracyte generated $35.2 million in cash from operations in the quarter, demonstrating strong underlying economics. The company closed the period with $439.1 million in cash, cash equivalents, and short‑term investments, providing ample flexibility to fund R&D, commercialization, and strategic initiatives.

Afirma Workflow Upgrades Drive Gains

Management completed the transition of Afirma to its V2 transcriptome workflow, which materially lowered no‑result rates and improved lab efficiency. This upgrade contributed roughly 400 basis points to Afirma’s volume growth in the quarter and should support broader sample recovery across the network.

Decipher’s Clinical Edge Fuels Growth

Decipher has maintained more than 20% quarterly growth since acquisition, with nearly 30% growth in high‑risk settings such as radical prostatectomy, biochemical recurrence, and metastatic disease. Management stressed an extensive clinical evidence base, including multiple Phase 3 trials like GUIDANCE, PREDICT‑RT, and the ENZIMET readout slated for a major oncology conference.

Pipeline Catalysts: Prosigna LDT and TruMRD

The Prosigna LDT commercial launch remains on track for midyear, supported by data from the OPTIMA Phase 3 trial expected to be presented at a key oncology meeting in June. Veracyte also plans to debut its TruMRD whole‑genome minimal residual disease platform initially in muscle‑invasive bladder cancer by the end of the second quarter, adding another potential growth driver.

Building Data Assets and Digital Capabilities

The company is expanding its Decipher GRID and Afirma GRID research databases, enhancing long‑term differentiation and partnerships. Meanwhile, digitization of Decipher slides is nearing completion with more than 350,000 images, setting the stage for collaborations in digital pathology and AI alongside multiple external validations and conference presentations.

Investing for Growth While Leveraging Scale

Non‑GAAP operating expenses rose 7% year over year to $64.6 million as Veracyte increased R&D and sales and marketing to support its expanding test menu. Even with this stepped‑up investment, the company delivered higher adjusted EBITDA and strong operating leverage, signaling disciplined spending and scalable infrastructure.

Guidance Conservatism and Optionality

Management emphasized that new products such as Prosigna LDT and TruMRD are not yet factored into current guidance, creating potential upside if launches gain traction. This conservative stance reflects both the binary nature of key trial outcomes and the desire to avoid overpromising ahead of guideline and reimbursement clarity.

Clinical, Seasonal, and Market Risks

The company’s outlook is closely tied to pivotal clinical readouts, particularly OPTIMA for Prosigna and ENZIMET for Decipher, both of which present binary risk around endpoints and timing. Veracyte also flagged prior‑period collections variability, seasonal heat‑related impacts on sample quality, uncertainties around guideline inclusion and reimbursement, and emerging competition in digital pathology and molecular diagnostics as adoption headwinds.

Outlook and Guidance

Veracyte raised its 2026 total revenue guidance to a range of $582 million to $592 million, implying 13% to 14% annual growth, with testing revenue expected to climb 16% to 18% excluding new tests. The company now targets full‑year adjusted EBITDA above 26%, expects Decipher to grow around 20%, Afirma to post high single‑digit to low double‑digit gains, and continues to exclude both new product revenue and future prior‑period collections from its outlook.

Veracyte’s earnings call painted a picture of a diagnostics company firing on multiple cylinders, with strong revenue growth, margin expansion, and a cash‑rich balance sheet. While investors must weigh trial, guideline, and competitive risks, the combination of accelerating Decipher momentum, Afirma workflow wins, and upcoming product launches positions the company for continued growth and potential upside to its conservative guidance.